Array Biopharma (ARRY) Tops Q4 EPS by 7c
Tweet
Share
E-mailGet Alerts ARRY Hot Sheet
Price: $4.06 -4.25%
EPS Growth %: -70.0%
Financial Fact:
Research and development for proprietary programs: 46.56M
Today's EPS Names:
VIVO, OCCI, ALZN, More
EPS Growth %: -70.0%
Financial Fact:
Research and development for proprietary programs: 46.56M
Today's EPS Names:
VIVO, OCCI, ALZN, More
Join SI Premium – FREE
Array Biopharma (NASDAQ: ARRY) reported Q4 EPS of ($0.09), $0.07 better than the analyst estimate of ($0.16). Revenue for the quarter came in at $12.3 million versus the consensus estimate of $10.29 million.
For earnings history and earnings-related data on Array Biopharma (ARRY) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Westinghouse said to seek over $50 billion valuation in planned IPO
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Barclays says AI trade is maturing, favors greater diversification
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
